Swiss Pilot Screening Study for Unruptured Intracranial Aneurysms to Prevent Subarachnoid Hemorrhage in Smokers
Unruptured intracranial aneurysms (UIAs) are potentially life-threatening vascular lesions that may rupture and cause aneurysmal subarachnoid hemorrhage (SAH), a condition associated with substantial morbidity and mortality. The prevalence of UIAs in the general population is approximately 3.2%. Current guidelines recommend screening primarily for individuals with a strong family history of UIA/SAH or autosomal dominant polycystic kidney disease (ADPKD). However, these groups account for only a minority of patients with UIAs.
Smoking is a major modifiable risk factor for UIA formation and rupture. Preliminary studies suggest that UIA prevalence may be substantially higher among smokers than in the general population, but prospective data are limited, particularly in men.
This prospective screening study aims to determine the prevalence of UIAs in active and recent smokers aged 30-60 years with a smoking history of at least 10 pack-years. We hypothesize that UIA prevalence in this population is significantly higher than in the general population and may approach that of established high-risk groups.
Participants will undergo non-contrast 3T magnetic resonance angiography (time-of-flight sequence). Baseline demographic and clinical characteristics, smoking habits, nicotine dependence, and quality of life will be assessed using REDCap questionnaires. Imaging findings will be communicated to participants, and those with detected aneurysms or relevant incidental findings will be referred for standard clinical evaluation. At 30 (±14) days after MRI, smoking habits, nicotine dependence, quality of life, and consequences of screening will be reassessed. The study will also evaluate the clinical implications and costs of screening.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Unruptured intracranial aneurysms (UIA) are an asymptomatic but potentially life-threatening cardiovascular condition. Rupture leads to aneurysmal subarachnoid hemorrhage (SAH), which is associated with high morbidity and mortality and causes 25% of all cerebrovascular-related deaths. In Switzerland, approximately 275'000 people harbor an UIA. Screening with imaging for detection of UIA to occlude them preventively and thus reduce SAH incidence is recommended according to current guidelines only in patients with ≥2 family members with a history of UIA/SAH or who suffer from autosomal dominant polycystic kidney disease (ADPKD). In these two groups, considered to be at high risk of having UIA, the prevalence of UIA is estimated to be 10%, compared with an approximate prevalence of 3.2% in the general population. However, patients with a positive family history for ≥2 family members or ADPKD represent an absolute minority of all UIA patients.
In contrast, smoking is common in SAH patients and is the most substantial risk factor for SAH. Approximately 40% of patients presenting with SAH are active smokers, and 39% of smokers with UIA will experience SAH during their lifetime. There are few but interesting data on the prevalence of UIA in middle-aged women who are smokers, as the incidence of SAH is highest in this subgroup. A retrospective nested case-control study in 30 to 60-year-old women who underwent head MRI for various indications found an UIA prevalence of 19% in female smokers compared to a prevalence of 1.9% in non-smoking females. Further, a recent small screening study found an UIA prevalence of 12% (5 out of 43) in female smokers.
Switzerland has implemented several tobacco control measures over the past 25 years, and tobacco use declined moderately until 2007. Since then, smoking prevalence has stabilized but remains relevantly high at approximately one-quarter of the population. 27% of the Swiss population (15 years and older) are active smokers, and 22% are former smokers. Smoking 20 or more cigarettes a day is considered heavy smoking, is prevalent in 6% of the population and is more common in men (8% men, 4% women). Although previous studies screened women exclusively, smoking is the most critical risk factor for SAH in both sexes, and Swiss men are more frequently heavy smokers than women.
Smoking cessation leads to a decrease in SAH incidence and is, contrary to ADPKD and positive family history of SAH/UIA, a risk factor that can be targeted with lifestyle modifications to prevent future SAH. These data and the continuing relevant health burden caused by smoking challenge the current screening approach towards a risk factor-based UIA screening strategy targeting smoking patients. To investigate the value of such risk factor-based screening, more extensive data on UIA prevalence in smokers is needed, particularly in men, because they are missing.
We hypothesize that the prevalence of UIA in active smokers is relevantly higher than the average UIA-prevalence of 3.2% and comparable to other high-risk groups (≥2 family members with a history of SAH/UIA, ADPKD) in whom guidelines currently recommend screening. Further, we hypothesize that in a relevant proportion of UIAs that could potentially be detected by such screening, the risk of natural history is higher than the risk of treatment resulting in a recommendation to perform preventive aneurysm occlusion or to undergo lifestyle modifications and follow-up with imaging.
After obtaining the signed informed consent and inclusion in the study, demographics, risk factors for SAH / UIA, QoL (15-D questionnaire), and nicotine dependence, will be assessed in an online questionnaire and with help of an online survey tool (REDCap). The 3T-MRI examination will be scheduled as a next step, and the appointment will be communicated to the participant. The 3T-MRI exams will take place at the Translational Imaging Senter in Sitem-insel. As MRI machine we will use a 3 T scanner (MAGNETOM Prisma, Siemens Healthcare) with a standard head coil. The time for acquiring the necessary TOF-angiography sequence is approximately 5 minutes. After the examination, participants can go directly home and no further examinations will be performed at this appointment. Within seven days after the examination, participants will be contacted by the study team via telephone and findings of the examination will be communicated. If a UIA or an incidental finding is detected, the patients will be called to a consultation in the outpatient clinic outside of the study and will be managed based on the finding with standard care. 30 (±14) days after the MRI examination, QoL, changes in smoking habits, and nicotine dependence will again be collected via an online questionnaire and with help of an online survey tool (REDCap). Furthermore, planned or completed interventions and consequences of the screening findings will be collected, as well as costs of screening and potential interventions will be recorded.
The maximum duration of the study after the MRI examination is 30 (±14) days. Depending on the availability of MRI slots, the period between inclusion and MRI examination may vary but should not exceed 8 (±4) weeks.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Johannes Goldberg, MD
- Número de telefone: +41316322409
- E-mail: johannes.goldberg@insel.ch
Estude backup de contato
- Nome: Nicole Söll
- Número de telefone: +41316323164
- E-mail: nicole.soell@insel.ch
Locais de estudo
-
-
Canton of Bern
-
Bern, Canton of Bern, Suíça, 3010
- Recrutamento
- Inselspital Bern, Department of Neurosurgery
-
Contato:
- Johannes Goldberg, MD
- Número de telefone: +41316322409
- E-mail: johannes.goldberg@insel.ch
-
Contato:
- Nicole Söll
- Número de telefone: +316323164
- E-mail: nicole.soell@insel.ch
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Women and men
- Age 30-60 years
- Active cigarette smoking with a cumulative exposure ≥ 10 pack-years
- Smoking cessation no longer than 6 months ago (<6 months
Exclusion Criteria:
- Contraindications to undergo MRI
- Patients with known UIA
- History of subarachnoid hemorrhage
- History of polycystic kidney disease, Ehlers-Danlos syndrome, Marfan's syndrome, fibromuscular dysplasia, Moya-Moya disease, or Loeys-Dietz syndrome, history of ≥2 family members with SAH/UIA
- Pregnancy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: screening for unruptured intracranial aneurysms
3T-MRI examination for Unruptured intracranial aneurysms |
After obtaining the signed informed consent, demographics, risk factors for SAH / UIA, QoL (15-D questionnaire), and nicotine dependence, will be assessed in an online questionnaire. The 3T-MRI examination will be performed. The time for acquiring the necessary TOF-angiography sequence is approximately 5 minutes. Within seven days after the examination, participants will be contacted by the study team via telephone and findings of the examination will be communicated. If a UIA or an incidental finding is detected, the patients will be called to a consultation in the outpatient clinic outside of the study and will be managed based on the finding with standard care. 30 (±14) days after the MRI examination, QoL, changes in smoking habits, and nicotine dependence will again be collected via an online questionnaire. Furthermore, planned or completed interinterventions and consequences of the screening findings will be collected. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
percentage of Unruptured intracranial aneurysms detected by screening
Prazo: 30 days after MRI
|
Diagnostic yield calculated as the percentage of UIAs detected by screening |
30 days after MRI
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Kind of interventions for detected Unruptured intracranial aneurysms (none, observation/lifestyle modifications, preventive occlusion)
Prazo: 30 days after MRI
|
Interventions for detected Unruptured intracranial aneurysms (none, observation/lifestyle modifications, preventive occlusion) |
30 days after MRI
|
|
Location of detected Unruptured intracranial aneurysms
Prazo: 7 days after MRI
|
7 days after MRI
|
|
|
Morphology of detected Unruptured intracranial aneurysms
Prazo: 7 days after MRI
|
7 days after MRI
|
|
|
Size of detected Unruptured intracranial aneurysms
Prazo: 7 days after MRI
|
7 days after MRI
|
|
|
Prevalence of incidental findings
Prazo: 7 days after MRI
|
7 days after MRI
|
|
|
Description of incidental MRI findings
Prazo: 7 days after Baseline MRI
|
7 days after Baseline MRI
|
|
|
Health Related Quality of Life (HRQoL) 15D
Prazo: at Baseline and 30 days after Baseline MRI
|
15D is a generic, comprehensive, 15-dimensional, standardized, self-administered measure of health-related quality of life (HRQoL). It includes the following 15 dimensions: breathing, mental function, speech (communication), vision, mobility, usual activities, vitality, hearing, eating, elimination, sleeping, distress, discomfort and symptoms, sexual activity, and depression. The maximum score is 1 (no problems on any dimension) and the minimum score is 0. A change of 0.02-0.03 has been observed to be such that people can feel the difference. |
at Baseline and 30 days after Baseline MRI
|
|
Effect of smoking dependency/smoking habits
Prazo: assessed before and after MRI
|
assessed before and after MRI
|
|
|
Costs of screening
Prazo: day 7 after MRI
|
Costs of screening compared to costs of SAH |
day 7 after MRI
|
|
Costs of potential interventions
Prazo: day 7 after MRI
|
Costs of potential interventions (including incidental findings) compared to costs of SAH |
day 7 after MRI
|
|
UIA detection rate with software
Prazo: day 7 after MRI
|
day 7 after MRI
|
|
|
Prevalence ouf detected UIAs stratified by sex
Prazo: day 7 after MRI
|
day 7 after MRI
|
|
|
Prevalence ouf detected UIAs stratified by pack-years
Prazo: day 7 after MRI
|
day 7 after MRI
|
|
|
Prevalence ouf detected UIAs stratified by age
Prazo: day 7 after MRI
|
day 7 after MRI
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Johannes Goldberg, MD, Inselspital Bern, Department of Neurosurgery
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2023-01023
- 2023 (Concessão/Contrato do NIH dos EUA)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .